NVCR
HEALTHCARENovoCure Ltd
$16.50+0.61 (+3.87%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving NVCR Today?
No stock-specific AI insight has been generated for NVCR yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$9.82$20.06
$16.50
Fundamentals
Market Cap$1.9B
P/E Ratio—
EPS$-1.53
Dividend Yield—
Dividend / Share—
ROE-0.5%
Profit Margin-0.3%
Debt / Equity—
Trading
Volume1.5M
Avg Volume (10D)—
Shares Outstanding115.8M
NVCR News
21 articles- [SCHEDULE 13G/A] NovoCure Ltd Amended Passive Investment DisclosureStock Titan·May 9, 2026
- 3 Overlooked Stocks Set to Soar in 2026Motley Fool·May 5, 2026
- NovoCure Stock Shows Strength With RS Upgrade; Investors Should Watch For Next EntryYahoo Finance·May 4, 2026
- International Markets and NovoCure (NVCR): A Deep Dive for InvestorsYahoo Finance·May 4, 2026
- NovoCure Limited (NASDAQ:NVCR) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?Yahoo Finance·May 2, 2026
- NovoCure Limited Q1 2026 Earnings Call SummaryMoby·May 1, 2026
- NovoCure (NVCR) Q1 2026 Earnings TranscriptMotley Fool·Apr 30, 2026
- Two Medical Stocks Skyrocket After Demolishing Views — And One Is About To Break OutYahoo Finance·Apr 30, 2026
- Sector Update: Health Care Stocks Gain Thursday AfternoonYahoo Finance·Apr 30, 2026
- NovoCure Q1 Earnings Call HighlightsMarketbeat·Apr 30, 2026
- NovoCure (NVCR) Reports Q1 Loss, Beats Revenue EstimatesYahoo Finance·Apr 30, 2026
- Novocure Reports First Quarter 2026 Financial ResultsYahoo Finance·Apr 30, 2026
- NovoCure (NVCR) Is Down 6.6% After Strong PANOVA-4 Phase 2 Data In Metastatic Pancreatic Cancer – Has The Bull Case Changed?Yahoo Finance·Apr 2, 2026
- Novocure to Report First Quarter 2026 Financial ResultsYahoo Finance·Apr 1, 2026
- Humacyte, Inc. (HUMA) Reports Q4 Loss, Misses Revenue EstimatesYahoo Finance·Mar 27, 2026
- Exchange-Traded Funds, Equity Futures Lower Pre-Bell Thursday Amid Ongoing Middle East TensionsYahoo Finance·Mar 26, 2026
- Novocure Announces Positive Topline Results from Phase 2 PANOVA-4 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Metastatic Pancreatic CancerYahoo Finance·Mar 26, 2026
- Is NovoCure (NVCR) Now Pricing In Too Much Pessimism After Prolonged Share Price SlumpYahoo Finance·Mar 26, 2026
- LENZ Therapeutics, Inc. (LENZ) Reports Q4 Loss, Misses Revenue EstimatesYahoo Finance·Mar 24, 2026
- Novocure's Optune Lua Gets Japan Reimbursement for NSCLC TreatmentYahoo Finance·Mar 9, 2026
- NovoCure (NVCR) Reliance on International Sales: What Investors Need to KnowYahoo Finance·Mar 2, 2026
All 21 articles loaded
Price Data
Open$0.00
Previous Close$15.88
Day High$0.00
Day Low$0.00
52 Week High$20.06
52 Week Low$9.82
52-Week Range
$9.82$20.06
$16.50
Fundamentals
Market Cap$1.9B
P/E Ratio—
EPS$-1.53
Dividend Yield—
Dividend / Share—
ROE-0.5%
Profit Margin-0.3%
Debt / Equity—
Trading
Volume1.5M
Avg Volume (10D)—
Shares Outstanding115.8M
About NovoCure Ltd
NovoCure Limited, an oncology company, is engaged in the development, manufacture and marketing of Optune for the treatment of a variety of solid tumors. The company is headquartered in Saint Helier, Jersey.
HEALTHCAREMEDICAL DEVICES
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICMEDICAL DEVICES
CIK—
Composite FIGI—
Share Class FIGI—